Increased COL11A1 expression, through the regulation of TGF-β3, activates CAFs via the NF-κB/IGFBP2 axis and also affects tumor aggressiveness and therapy resistance through the TGF-β1/MMP3 axis. This evidence concerns the gene TGFB1 and neoplasm.